Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NBI 921352

Drug Profile

NBI 921352

Alternative Names: NBI-921352; XEN 901

Latest Information Update: 28 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xenon Pharmaceuticals
  • Class Antiepileptic drugs; Small molecules
  • Mechanism of Action Nav1.6 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Epilepsy
  • Discontinued Dravet syndrome

Most Recent Events

  • 25 Apr 2020 Phase-I clinical trials in Epilepsy (In children) in Canada (PO) before April 2020
  • 25 Apr 2020 Phase-I clinical trials in Epilepsy (In volunteers) in Canada (PO, Tablet) before April 2020
  • 25 Apr 2020 Adverse events and pharmacokinetics data from a phase I trial in Healthy volunteers (PO, Capsule, Tablet) presented at the 72nd Annual Meeting of the American Academy of Neurology (AAN-2020)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top